Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy

Taking stock of the drug industry, from the lab to the medicine chest

June 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mario Tama/Getty Images STAT+ | Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy "This is a big deal for Avidity and the FSHD field," analysts wrote in a note to investors. By Jason Mast Watch: How pharmacy benefit managers influence drug pricing In Part 2 of "Behind the Counter," a STAT video series exploring high prescription drug prices, the pricing role of pharmacy benefit managers is examined. By Anna Yeo STAT+ | Why Google and Microsoft can't defuse U.S. health care's ticking cybersecurity problem Experts say the initiative falls short of what's needed to keep Americans' health data safe, and prevent attacks that cripple health systems. By Casey Ross and Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser